Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266243 | 0.96 | HTT (0.52) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL14036502 | 0.96 | GAA (0.50) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL13266190 | 0.91 | HTT (0.48) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL13668721 | 0.91 | HTT (0.48) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL13668609 | 0.91 | HTT (0.48) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL13082579 | 0.91 | HTT (0.48) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL16361395 | 0.90 | BCHE (0.48) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL13266247 | 0.89 | HTT (0.50) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL18995785 | 0.87 | BCHE (0.45) | HTTSMN1; SMN2TDP1L3MBTL1GAA | |
| SCHEMBL13427514 | 0.85 | HTT (0.47) | HTTSMN1; SMN2TDP1L3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| US-20100159351-A1 | MEMBRANE-ELECTRODE ASSEMBLY, AND MEMBRANE-ELECTRODE-(GAS DIFFUSION LAYER) ASSEMBLY AND SOLID POLYMER FUEL CELL EACH COMPRISING THE SAME | SUMITOMO CHEMICAL COMPANY LIMITED | 2010-06-24 | — | — | US | disclosed |
| US-20090253015-A1 | POLYARYLENE BLOCK COPOLYMER AND USE THEREOF | SUMITOMO CHEMICAL COMPANY ,LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | HTT 2006/4885SMN1; SMN2 4123/4885TDP1 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.